Professional Documents
Culture Documents
Agenda
Evolution of GCP. ICH-GCP. Differences and Similarities between ICH-GCP , Indian GCP and Schedule-Y Key Players in Clinical Research and their checklists
Evolution
Nuremberg Code, 1947 Declaration of Helsinki, 1964 2001 ICH GCP guidelines, 1996 Ethical Guidelines for Biomedical Research in Human Subjects (ICMR), 2000 GCP Guidelines, CDSCO, New Delhi, 2001
ICH-GCP-Introduction
Good Clinical Practices (GCP) is an international ethical & scientific quality standard for designing, conducting, recording & reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that rights, safety & well being of trial subjects are protected, consistent with the principles that have their origin in the declaration of Helsinki, and that the clinical trial data are credible
ICH GCP-Section 1
Section 1- Glossary of various terms, eg... Adverse drug reaction & Adverse Event Case report form & Clinical Study Report Coordinating Committee & Contract Research Organization Independent Ethics Committee & Institutional Review Board Investigator & Investigators Brochure
has received prior institutional review board (IRB)/ independent ethics committee (IEC) approval/favourable opinion. 2.7 The medical care and medical decisions for subjects should be the responsibility of a qualified physician
2.8 Each individual involved in conducting a trial should be qualified by education, training & experience to perform his respective task
2.11 The confidentiality of records that could identify patients should be protected, respecting the privacy and confidentiality rules in accordance with the applicable regulatory requirements
ICH-GCP-Section 3
Institutional Review Boards/ Independent Ethics Committee
ICH-GCP: Section 5
Sponsor Responsibilities
Sponsor
An individual, company, institution, or organization which takes responsibility for the initiation, management, and/or financing of a clinical trial
Sponsor Responsibilities
Designate Medical Expertise :who will be readily available to advise on trial related medical questions or problems. (Section
5.3)
Trial design (Section.5.4), Trial management, Data handling and Record Keeping (Section 5.5) and Investigator selection (Section 5.6), Allocation of Responsibilities (Section 5.7) Compensation to Subjects and Investigators (Section 5.8), Financing (Section 5.9) Submission to regulatory authorities (Section 5.10) Confirmation of review by IRBs (Section5.11)
Supplying and Handling Investigational Product(s) (Section 5.14) and Record Assess (Section 5.15) Safety Evaluation (Section 5.16) and Adverse Drug Reaction
Reporting (Section 5.17)
Monitoring
The act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, SOPs, GCP, and the applicable regulatory requirements
ICH-GCP: Section 6
CLINICAL TRIAL PROTOCOL AND PROTOCOL AMENDMENT(S)
Protocol
Document describing all aspects of the study Well designed and thoroughly considered Well structured Complete
Sec 6.13:
ICH-GCP: Section 7
Informed Consent
ICH-GCP: Section 8
ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A
CLINICAL TRIAL
Essential Documents are those documents which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. These documents serve to demonstrate the compliance of the investigator, sponsor and monitor with the standards of Good Clinical Practice and with all applicable regulatory requirements
Audit certificate (if required) Final trial close-out monitoring report Treatment allocation and decoding documentation returned to sponsor to document any decoding that may have occurred Final report by investigator to IRB where required Final report by investigator to regulatory authorities where applicable to document completion of the trial Clinical study report to document results and interpretation
Drug Technical Advisory Board (DTAB), the highest technical body under D&C, Act, has endorsed adoption of this GCP guideline for streamlining the clinical studies in India
These guidelines have been evolved with consideration of WHO, ICH, USFDA and European GCP guidelines as well as the Ethical Guidelines for Biomedical research on Human Subjects issued 70 by the Indian Council of Medical Research.
STRUCTURE ICH E6
Glossary Principles IRB/IEC Investigator Sponsor Protocol Investigators Brochure Essential Documents
Indian GCP
Definitions Pre-requisites Responsibilities Records & Data Quality Assurance Statistics Special Concerns Appendices
71
Regulatory Authority
Ethics Committee
72
GCP IMPLEMENTATION
Want to
Attitude
Performance
Knowledge
What to Why to
Skills
How to
73
Schedule Y DRUGS AND COSMETICS (IIND AMENDMENT) RULES, 2005 NOTIFICATION the 20th January, 2005
Amendment
Enacted by Parliament in the Fifty-sixth year of Republic of India Published in the Gazette of India Part-II, section 3, sub-section (i) vide G.S.R. 32(E), dated 20th January, 2005
74
Schedule Y
Regulation and guidelines for permission to import and / or manufacture of new drugs for sale or to undertake clinical trials
It has outlined extensive study criteria in line with the globally accepted formats such as ICH and US FDA guidelines
REFER TO RULES 122A, 122B, 122D, 122DA, 122DAA and 122E
75
122-A : Application for permission to import new drug 122-B : Application for approval to manufacture new drug 122-D: Permission to import or manufacture FDC 122-DA : Permission to conduct clinical trials for New Drug / Investigational New Drug
Appendix I Data to be submitted along with the application to conduct clinical trials / import / manufacture of new drugs for marketing in the country. Appendix II Structure, contents & format for clinical study reports Appendix IV Animal pharmacology Appendix VI Fixed Dose Combinations (Fdcs)
Appendix I-A Data required to be submitted by an applicant for grant of permission to import &/or manufacture a new drug already approved in the country. Appendix III Animal toxicology (non-clinical toxicity studies)
Any one designated Investigator should by the investigator to sign the form. (2.4.3.1) conduct and to sign the consent form.(4.8.8)
79
Indian GCP
Schedule-Y
Fairly small (5-7 members). At least 7 members. Not Explained Not Explained. The quorum should have a The quorum should minimum of 5 members. have at least 5 members. Maximum number is not 12 to 15 is the maximum Maximum number is detailed. recommended number. not detailed. Not recommended. Member Secretary belongs Not recommended. to the same Institution.
DRUG LABEL
ICH GCP Not Explained Indian GCP Schedule-Y Should include name Not Explained and contact numbers of investigator and name of institution. (2.3.1.6)
DOCUMENT RETENTION
ICH GCP Indian GCP The records are Study related linked to marketing documents/materials approval should be safe guarded by the sponsor for 3 years. (3.1.5) Schedule-Y Not Explained
POWERS OF IEC
ICH GCP It is the responsibility of independent datamonitoring committee (IDMC) Indian GCP Schedule-Y IEC has power to Not Explained order discontinuation of a trial if goals of the trial have already been achieved or unequivocal results obtained. (2.4.2.6)
INVESTIGATORS QUALIFICATION
ICH GCP Not Recommended Indian GCP Should be qualified as per the requirement of the Medical Council of India (MCI). (3.3.1) Schedule-Y Not Explained
Investigators checklist - 1
Interest, expertise, time and facilities Interaction with sponsor
Protocol, CRF, PIS and ICF Financial grant Publication policy
Investigators checklist - 2
Implementation Organizing, briefing and supervising the team Facilitating informed consent process Completing and signing CRFs Reporting SAE Interacting with monitor Reviewing and approving final report Archiving source documents Preparing for audit and/or inspection
Sponsors checklist - 1
Scientific, regulatory and ethical basis of the protocol, PIS and ICF Investigators qualifications, training and experience Regulatory and ethical approvals Publication policy Quality of trial supplies Initiation, monitoring and audit
Sponsors checklist - 2
Data management and analysis Drafting of study report Preparation for inspection Archives of source documents
Regulators checklist
Periodic review of current regulations from scientific and ethical angles Advance consultation to sponsors on protocols
Efficacy and safety criteria Comparator product
Advisory panels for review of applications and decision making Inspection of investigational centers